Kornimate/medical-research-clean huggingface dataset:
exploratory study of natural killer cells in human skin

Conditions: Atopic Dermatitis; Contact Dermatitis; Psoriasis; Lichen Planus; Graft Versus Host Disease; Melanoma

Summary: natural killer (nk) cells play a unique role during innate immune responses as they are able to recognize and eliminate, without specific sensitization, tumors, microbe-infected cells as well as allogeneic cells.in a first time, we will characterize the tissue distribution, the phenotype and the effector functions of nk cells present in the human healthy skin.

then, we will define whether these parameters are qualitatively/ quantitatively modified in the following skin pathologies: a) atopic dermatitis; b) contact dermatitis; c) psoriasis ; d) lichen planus ; e) gvh (graft versus host disease) ; (f) melanoma.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * consent obtained after healthy donor or patient information. * patients suffering from one of the following diseases: a) atopic dermatitis ; b) contact dermatitis; c) psoriasis ; d) lichen planus ; e) gvh ; f) melanoma. exclusion criteria: * age below 18, * pregnant or breastfeeding women, * persons under guardianship, persons without social security, prisoners, persons hospitalized without consent on the basis of french laws l. 3212-1 et l. 3213-1. patients affected by hiv infection, aids, hepatitis a, b or c infection. * neutropenia \<1000/mm3. * thrombopenia \<50 000/mm3.
vestibular evaluation after vestibular schwannoma treatment

Conditions: Dizziness

Summary: vestibular schwannoma is a benign tumor located on the vestibular nerve. patient could present dizziness symptoms cause to the tumor, and at least after the treatment by gamaknife radiosurgery or microsurgery resection. only few studies keep the interest about dizziness symptoms and treatment modality in vestibular schwannoma. in the study dizziness symptoms were compared before and after the treatment of vestibular schwannoma by radiosurgery gammaknife or microsurgery resection. 2 scales were used : dizziness handicap inventory (dhi) and dizziness functionnal scale (aao).


Eligibility criteria:
inclusion criteria: * patient treated of an one side vestibular schwannoma between 01/01/2012 and 31/12/2017, follow at the grenoble university hospital * treatment : gamaknife radiosurgery or microsurgery resection * no opposition of the patient exclusion criteria: * association of gamaknife radiosurgery and microsurgery resection * bilateral vestibular schwannoma

Keywords: vestibular schwannoma gammaknife radiosurgery vestibular evaluation
clinical comparison of treatment strategies in ampc beta-lactamase producing enterobacterales in a swiss tertiary care hospital

Conditions: Infection With AmpC Beta-lactamase Producing Enterobacterales

Summary: this study is to investigate the recent epidemiological trends and the treatment outcome in terms of the length of hospital stay, the relevant renal and neurological side effects, risk factors for developing these side effects, the selection of more resistant pathogens under therapy as well as the incidence of clostridium difficile infections under treatment.

increasing resistance among enterobacterales to beta-lactam antibiotics is globally a major concern in the antibiotic resistance crisis. in gram-negative bacteria it evolves primarily through the production of beta-lactamases that allow the rapid hydrolysis of common antibiotics - most notably 3rd generation cephalosporins. particularly, the production of ambler class c beta-lactamase (ampc) is a very concerning and unique resistance mechanism as so called derepressed mutants can be induced during treatment. information on recent epidemiological trends as well as comparative information about the treatment strategies (cefepime versus piperacillin/tazobactam versus carbapenems) for infections with ampc-producing enterobacterales in switzerland is still lacking. this study is to investigate the recent epidemiological trends and the treatment outcome in terms of the length of hospital stay, the relevant renal and neurological side effects, risk factors for developing these side effects, the selection of more resistant pathogens under therapy as well as the incidence of clostridium difficile infections under treatment.

Eligibility criteria:
inclusion criteria: * patients with detection of ampc beta-lactamase producing enterobacterales 1. in a blood culture (any ward) 2. in a clinical sample of the lower respiratory tract (only intensive care unit) exclusion criteria: * patients with documented refusal of subsequent use of their data

Keywords: antibiotic resistance ambler class c beta-lactamase (ampc) carbapenem resistance minimum inhibitory concentrations (mics) cefepime piperacillin/tazobactam carbapenem clostridium difficile infections epidemiological trends
extension of prior study evaluating safety and tolerability of two doses of betaseron® to treat relapsing-remitting multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with multiple sclerosis.

this study has previously been posted by berlex, inc. berlex, inc. has been renamed to bayer healthcare pharmaceuticals, inc. bayer healthcare pharmaceuticals, inc.is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * signed and dated statement of informed consent * completion of protocol 307000a * negative serum pregnancy test results * agreement to adequate contraception, for female patients exclusion criteria: * pregnancy or lactation * history of alcohol or drug abuse * inability to administer subcutaneous injections either by self or by caregiver * medical, psychiatric or other conditions that compromise the patient's ability to give informed consent, to understand the patient information, to comply with the study protocol, or to complete the study * any significant change in the patient's medical condition after enrollment in study 307000a which would have lead to his/her exclusion from participation that study

Keywords: relapsing multiple sclerosis interferon beta 1b betaferon betaseron
whole-body vibration and manual ability

Conditions: Body Weight; Vibration; Motor Activity

Summary: purpose: to evaluate the short-term effects of whole-body vibration (wbv), using reciprocating plate technique, on manual ability performance in healthy younger. material and methods: 38 healthy young volunteers were randomized to wbv group (n=19; 6 men, 13 women; mean age 21, 3.8yrs) or control group (n=19; 6 men, 13 women; mean age 20.5, 3.5yrs). the subjects in the wbv group performed one series of five consecutive repetitions of 60 sec unsynchronised wbv (zeptoring, scisen gmbh, germany; 4 hz, amplitude 3mm) with a 1-min pause between administrations, three times a week. the controls did not receive any training. both groups were evaluated at baseline and after intervention, in the rey juan carlos university´s gait analysis laboratory. four outcome measures of purdue pegboard test (ppt): preferred hand (ph), non-preferred hand (nph), both hands (bh) and assembly (a) was performed baseline and 5 min after intervention.


Eligibility criteria:
inclusion criteria: - healthy subjects aged between 18 and 30 years. exclusion criteria: * contraindication for wbv: pregnancy, recent fractures, malignancies, kidney stones, cardiac pacemaker, infectious disease or recent thromboembolic. * subjects with any musculoskeletal o neurological disorders that affected their hands. * individuals already treated with wbv were excluded.
safety of liraglutide in subjects with liver impairment and in subjects with normal liver function

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this trial is to investigate liraglutide in subjects with mild, moderate and severe degrees of hepatic impairment compared with subjects with normal hepatic function.


Eligibility criteria:
inclusion criteria: * subjects with normal hepatic function and liver parameters within normal range * subjects with stable hepatic impairment classified as child-pugh grade a, b or c * body mass index between 18.5-40.0 kg/m\^2 (both inclusive) exclusion criteria: * known or suspected allergy to trial product or related products * liver transplanted subjects * cardiac problems * uncontrolled treated/untreated hypertension * signs of acute liver insufficiency * positive hiv (human immunodeficiency virus) 1+2 antibodies * cancer or any clinically significant disease or disorder except for conditions associated with the hepatic impairment * impaired renal function * smoking of more than 10 cigarettes per day, or the equivalent for other tobacco products * habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the investigator
impendia- pen vs dianeal only improved metabolic control in diabetic capd and apd patients

Conditions: ESRD; Diabetes; CAPD; APD

Summary: primary objective: to demonstrate that use of glucose sparing prescriptions (pen vs dianeal only) in diabetic (type 1 and type 2) continuous ambulatory peritoneal dialysis (capd) and automated peritoneal dialysis (apd)patients leads to improved metabolic control as measured by the magnitude of change from the baseline value in the hba1c levels. secondary objectives: to demonstrate that use of glucose-sparing pd solutions (pen vs dianeal only) in diabetic (type 1 and type 2) capd and apd patients leads to lower glycemic-control medication requirements, decreased incidence of severe hypoglycemic events requiring medical intervention, improved metabolic control, nutritional status, and quality of life. in a subgroup of patients, the impact of glucose-sparing pd solutions (pen vs dianeal only) on abdominal fat and left ventricular (lv) structure and function will be assessed.

the data represented in this module is a pooled analysis of the following 3 studies: nct00567489 (protocol id 31998), nct00567398 (protocol id 34202), nct01219959 (protocol id51067). given that the glucose content of the pd solutions is similar, the pooling of the results were considered a valid method to answer the underlying research questions.

Eligibility criteria:
inclusion criteria: 1. m/f patients 18 years of age or older 2. diagnosis of esrd (gfr ≤ 15 ml/min) 3. capd or apd using only dianealand/or physioneal, at least 1 exchange of 2.5% or 4.25% dextrose/day, no prescribed dry time 4. dm (type 1 and 2) on glycemic-control medication, for 90 days 5. hba1c \> 6.0% but ≤ 12.0% 6. blood hemoglobin ≥ 8.0 g/dl, but ≤ 13.0 g/dl exclusion criteria: 1. cardiovascular event within the last 90 days 2. ongoing clinically significant congestive heart failure (nyha class iii or iv) 3. allergy to starch-based polymers 4. glycogen storage disease 5. maltose, or isomaltose intolerance 6. peritonitis, exit-site or tunnel infection treated with antibiotics within last 30 days 7. mean arterial pressure (map) ≥ 125 mm hg, or volume depleted (map \< 77) at screening. 8. serum urea \> 30 mmol/l 9. exposure to extraneal or nutrineal within the last 60 days prior to screening visit, day 1. 10. receiving rosiglitazone maleate

Keywords: esrd diabetes capd apd
high or low dose postpartum oxytocin at the time of cesarean birth

Conditions: Postpartum Hemorrhage; Pregnancy Complications; Cesarean Section Complications

Summary: this is a study to investigate whether it is feasible to conduct a randomized controlled trial (rct) of a high dose of oxytocin versus the standard low-dose oxytocin. further the investigators, aim to assess whether there are differences in health outcomes between both arms of the study.

due to risks of postpartum hemorrhage, defined by the american college of obstetricians and gynecologists, as an estimated or quantitative blood loss of greater than 1000 milliliters, uterotonics, or medications aimed at increasing uterine tone and reducing blood loss at the time of birth, are commonly administered. based on a cochrane network meta-analysis, most organizations endorse the administration of 10 international units (iu) of oxytocin during delivery. however, the world health organization specifies that during a cesarean birth, the 10 iu should be administered using a bolus dose and an infusion, though an optimal infusion rate has yet to be agreed upon. the use of a higher rate of oxytocin may confer a reduction in overall blood loss and subsequent maternal health outcomes (e.g., postoperative anemia, hypotension) and healthcare resource utilization (e.g., need for additional uterotonics and surgical procedures to control bleeding, administration of blood products). however, it is unknown whether it is feasible to conduct a randomized controlled trial to investigate the use of high (i.e., oxytocin rate of 900 ml/hr immediately after the delivery of the placenta) versus low-dose oxytocin (i.e., 300 ml/hr for planned cesarean births or 600 ml/hr for intrapartum cesarean births).

Eligibility criteria:
inclusion criteria. * age 18 or greater * english or spanish speaking * individuals undergoing a scheduled or unscheduled cesarean delivery exclusion criteria * patient on therapeutic anticoagulation * patient with hypertensive disorder of pregnancy or chronic hypertension * patient with preexisting bleeding disorder * patient with preexisting cardiac disease * patient with severe asthma, defined as the need for two or more agents for disease control, or bronchospasm * patient undergoing planned cesarean hysterectomy

Keywords: oxytocin cesarean delivery postpartum hemorrhage
the associated factors with fatigue in older adults living in a rest home

Conditions: Fatigue; Older People--Abuse of

Summary: fatigue is an important and prevalent problem in older adults. the ratio of fatigue may rise in older adults who live in nursing homes/rest homes. in the literature, a few studies investigated the prevalence of fatigue, and there is no study explaining the associated factors. the aim of the present study is to investigate the prevalence of fatigue in rest home residents and to determine the associated variables with fatigue.


Eligibility criteria:
inclusion criteria: * age older than 65 years * able to walk with/without walking device * living at a rest home for at least 12 months * being voluntary for all assessments exclusion criteria: * had a cognitive problem (mmse\<24 scores) * had a neurologic disorder * had a cancer history * had uncontrolled cardiopulmonary dysfunction

Keywords: fatigue physical function strength older adults nursing homes
su011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma

Conditions: Carcinoma, Renal Cell

Summary: the purpose of this study is to test whether su011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (rcc).


Eligibility criteria:
inclusion criteria: * histologically confirmed renal cell carcinoma of clear cell histology with metastases * evidence of measurable disease by radiographic technique * eastern cooperative oncology group \[ecog\] performance status of 0 or 1 exclusion criteria: * prior systemic (including adjuvant or neoadjuvant) therapy of any kind for rcc * history of or known brain metastases * serious acute or chronic illness or recent history of significant cardiac abnormality
role of modified robbery exercises on scapular dyskinesis in frozen shoulder

Conditions: Frozen Shoulder

Summary: the study aims to find out the role of the modified robbery exercises in the management of scapular dyskinesia in patients with frozen shoulders. this single-blind randomized clinical study will be conducted at approved study center in lahore pakistan in line with the ethical principles stated in declaration of helsinki. pain, muscle activation, rom, scapular dyskinesia, muscle strength, functional limitation and participants' wellbeing will be recorded at baseline, after week three, and after week six in both intervention and control groups.

scapular dyskinesia is regarded as the altered scapular kinematics, presenting with increased scapular upward rotation and eminence of the medial border in patients with shoulder injuries. patients with frozen shoulder present with a certain degree of scapular dyskinesia. the objective of the study is to find out the role of the modified robbery exercises in the management of scapular dyskinesia in patients with frozen shoulders. this single-blind randomized clinical study will be conducted at approved study center in lahore pakistan. the study will abide by the ethical principles in line with the declaration of helsinki. baseline data of the participants of pain, muscle activation, rom, scapular dyskinesia, muscle strength, functional limitation and participants' wellbeing will be recorded. group a will receive the modified robbery exercises three days a week for six weeks, group b will receive the conventional physical therapy protocol three days a week for six weeks. outcomes will be assessed at baseline, after week three, and after week six. data will be recorded using questionnaires, proforma and the other listed outcome measurement tools. on the base of normality of the data appropriate parametric test or non-parametric test will be applied for intra and inter group comparison.

Eligibility criteria:
inclusion criteria: * patients of both genders * patients of age 35 to 55 years * modified lateral scapular slide test score \> 1.4 cm * pain on vas ≥4 out of 10. * pain in the shoulder for at least 3 months * diagnosed unilateral frozen shoulder * limited scapular upward rotation, capsular pattern (more limited external rotation than abduction), * scapular dispositioning and visible inferior medial border prominence. exclusion criteria: * patients with frozen shoulders having less than 90 degrees of flexion and abduction. * participants with cervical radicular pain * pregnant females * presence of red flags to the treatment * history of recent trauma to the spine or the shoulder complex. * history of recent shoulder surgery * any neurological deficit i.e winged scapula * other pathologies like cervical myelopathy and prolapsed cervical disc. * known cases of neurological, radiculopathy, and inflammatory diseases. * having spinal deformities such as scoliosis or kyphosis. * vestibular or respiratory disorder, auditory or cognitive impairment * taking medication that may affect the balance and coordination.
rollover extension clinical trial to evaluate the long-term safety and efficacy of kt-301 (formerly us-apr2020) in subjects with ckd iv completing the us-apr2020-01 study

Conditions: Chronic Kidney Disease stage4

Summary: this is an open-label rollover extension clinical trial to evaluate the long-term safety and efficacy of kt-301 (formerly us-apr2020) in subjects with ckd iv who completed the us-apr2020-01 study

kidney diseases are a global public health problem that affects over 200 million people worldwide. it is estimated that about 30 million adults in the united states have chronic kidney disease (ckd) and most are undiagnosed. in addition, ckd represents the ninth leading cause of death in the united states. kidney diseases also represent great socioeconomical cost worldwide. in the united states, treating medicare beneficiaries with ckd costed over $79 billion, and treating people with end stage kidney disease (eskd) costed an additional $35 billion in 2016. to date, there is no cure for ckd. ckd is accompanied by altered pathogenic gut bacteria, inflammation, and accumulation of uremic toxins in the blood. these blood uremic toxins can diffuse passively into the bowel. scientific research has shown that probiotic bacteria could metabolize various uremic toxins such as urea, uric acid and creatinine. in addition, by supplementing the gut microbiome with probiotic bacteria, it is possible to metabolize the nitrogenous waste products and other toxins which diffuse into the gut, and thus lower levels of inflammation and blood uremic toxins. kt-301 (formerly us-apr2020) is a probiotic formulation of bacteria intended to restore the gut bacteria balance to improve the removal of uremic toxins in the bowel in ckd patients. this is an open label, multicenter, rollover extension study to provide kt-301 to subjects who were previously enrolled into and completed the placebo-controlled study, us-apr2020-01. subjects will roll over to the long-term extension study at the last visit of the us-apr-2020-01 study. all subjects who completed the us-apr2020-01 study will be eligible to enroll in this study. the purpose of this open-label study is to evaluate the long-term safety and efficacy of the live biotherapeutic product, kt-301, in the management of patients with ckd stage iv.

Eligibility criteria:
inclusion criteria: * completion of us-apr2020-01 study * adults between the ages of 18-80 years exclusion criteria: * did not participate in the placebo-controlled study us-apr2020-01 * withdrew from us-apr2020-01 study prior to completing the 6 months treatment for any reason * unwilling or unable to visit the site for the follow-up visits
dwi breast mri in dense breast: a clinical trial to assess the efficacy and diagnostic accuracy of diffusion weighted imaging in dense breast tissue

Conditions: Dense Breast Parenchyma; Breast Cancer Detection; DWI

Summary: his clinical trial aims to evaluate the efficacy and diagnostic accuracy of diffusion weighted imaging (dwi) in breast mri for women with dense breast tissue. dwi is investigated as an adjunctive method to improve early tumor detection in women with dense breasts, a group at high risk for delayed diagnosis due to limited visibility in mammography. study purpose: to assess the utility of diffusion weighted imaging (dwi) in improving diagnostic accuracy for patients with dense breasts.


Eligibility criteria:
inclusion criteria: * women aged 40-75 years. * patients with dense breast tissue, classified according to bi-rads (breast imaging-reporting and data system). * patients who previously underwent breast mri, including diffusion weighted imaging (dwi). * availability of histopathological confirmation for breast lesions (biopsy results). exclusion criteria: * patients with a known allergy to gadolinium-based contrast agents. * pregnant or breastfeeding women at the time of imaging. * presence of metallic implants or other mri-incompatible devices. * patients with incomplete imaging datasets (e.g., missing dwi sequences or non-standardized protocols). * prior history of breast cancer treatment (surgery, chemotherapy, or radiotherapy) before the imaging study.

Keywords: breast mri dwi dense breast